| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-02-28 | GSK2586184 (formerly GLPG0778) | systemic lupus erythematosus |
2 | GSK (UK) | Autoimmune diseases |
| 2014-02-28 | GSK2586184 (formerly GLPG0778) | ulcerative colitis |
2 | GSK (UK) | Autoimmune diseases – Inflammatory diseases |
| 2014-02-26 | Prohema® (16, 16-dimethyl prostaglandin E2, or dmPGE2, modulated cord blood) | adult patients undergoing hematopoietic stem cell (HSC) transplantation for hematologic malignancy | 1b | Fate Therapeutics (USA - CA) | Cancer - Oncology |
| 2014-02-25 | Pexa-Vec | advanced solid tumors | 1-2 | Transgene (France) | Cancer - Oncology |
| 2014-02-21 | ISIS-SMNRx (antisense oligonucleotide targeted to the SMN2 gene) | spinal muscular atrophy (SMA) |
Isis Pharmaceuticals (USA) | Neuromuscular diseases - Rare diseases - Genetic diseases | |
| 2014-02-20 | masitinib in combination with docetaxel | metastatic castrate resistant prostate cancer | 3 | AB Science (France) | Cancer - Oncology |
| 2014-02-19 | Nerventra® (laquinimod) | relapsing remitting multiple sclerosis (RRMS) | 3 | Teva Pharmaceutical Industries (Israel) Active Biotech (Sweden) | Autoimmune diseases - Neurodegenerative diseases |
| 2014-02-18 | BAY94-9027 [recombinant human factor VIII (rFVIII) - damoctogog alfa pegol] | hemophilia A |
3 | Bayer (Germany) | Hematologic diseases - Genetic diseases |
| 2014-02-17 | rivaroxaban | long-term, secondary prevention of symptomatic venous thromboembolism( VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE) | 3 | Bayer (Germany) | Cardiovascular diseases |
| 2014-02-17 | GLPG0974 | ulcerative colitis | 2a | Galapagos (Belgium) | Autoimmune diseases - Inflammatory diseases |
| 2014-02-13 | laquinimod | Crohn's Disease (CD) |
2 | Teva Pharmaceuticals (Israel) Active Biotech (Sweden) | Autoimmune diseases - Inflammatory diseases - Digestive diseases |
| 2014-02-12 | ETS2101 (dexanabinol) | solid tumors | 1 | e-Therapeutics | Cancer - Oncology |
| 2014-02-12 | IMAB027 | ovarian cancer | 1-2 | Ganymed Pharmaceuticals (Germany) | Cancer - Oncology |
| 2014-02-11 | XEN-0501 | cough associated with chronic obstructive pulmonary disease (COPD) |
2a | Ario Pharma (UK) | Respiratory diseases - Inflammatory diseases |
| 2014-02-11 | KU-5039 | insulin resistance diabetes |
2 | Kareus Therapeutics (Switzerland) | Metabolic diseases |
| 2014-02-11 | remimazolam | general anaesthesia in cardiovascular surgery | 2 | Paion (Germany) | CNS diseases - Cardiovascular diseases |
| 2014-02-10 | NBTXR3 | soft tissue sarcoma (STS) |
1 | Nanobiotix (France) | Cancer - Oncology |
| 2014-02-06 | Vyvanse® (lisdexamfetamine dimesylate) | major depressive disorder (MDD) in adults who inadequately responded to antidepressant monotherapy with a SSRI or SNRI |
3 | Shire (UK-USA) | Mental diseases - CNS diseases |
| 2014-02-06 | TG01 | operable pancreatic cancer | 1-2 | Targovax (Norway) | Cancer - Oncology |
| 2014-02-05 | Dysport® Next Generation (DNG) | cervical dystonia |
3 | Ipsen (France) |
